Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
St. Michael's University Hospital, 2nd Internal Ambulance, Bratislava, Slovakia.
Genet Test Mol Biomarkers. 2021 Apr;25(4):302-306. doi: 10.1089/gtmb.2020.0277.
Circulating microRNA-21 (miR-21) has been utilized as a diagnostic tool in the assessment of heart failure (HF). Blood constitution may be altered when HF occurs and miR-21 may affect hematopoiesis. Sample hemolysis may influence the determination of circulating miRNAs, challenging the diagnostic use of miRNAs. We examined the relationship between blood measurements and miR-21 levels in ambulant chronic HF patients with reduced ejection fraction (HFrEF; = 19). Healthy volunteers ( = 11) served as controls. Serum miR-21 levels were measured through quantitative reverse transcription polymerase chain reaction (RT-qPCR) and we calculated the hemolysis score (H-score). Study was approved by an Institutional Review Board (EK FaF UK 02/2018). MiR-21 serum levels were reduced in HFrEF patients compared with the controls ( < 0.05), without relationship to New York Heart Association class, left ventricular ejection fraction or N-terminal prohormone of brain natriuretic peptide levels. MiR-21 levels decreased markedly in anemic patients, compared with those with normal hematocrits ( < 0.05). We found a significant relationship between miR-21 to hematocrit ( < 0.05) and hemoglobin concentration ( < 0.05). Importantly, we found a correlation between hematocrit and sample H-score ( < 0.05) in the cohort of HFrEF patients; however, there was no correlation between hemolysis and miR-21. Circulating miR-21 levels were decreased in HFrEF patients and hematocrit was identified as a factor associated with this abnormality. This suggests that miR-21 mirrors other characteristics of HFrEF patients rather than the standard identifiers of HF severity and progression.
循环 microRNA-21（miR-21）已被用作心力衰竭（HF）评估中的诊断工具。当 HF 发生时，血液成分可能会发生变化，miR-21 可能会影响造血。样本溶血可能会影响循环 miRNA 的测定，从而影响 miRNA 的诊断应用。我们检查了 19 名射血分数降低的慢性 HF 患者（HFrEF）和 11 名健康志愿者（对照组）的血液测量值与 miR-21 水平之间的关系。通过定量逆转录聚合酶链反应（RT-qPCR）测量血清 miR-21 水平，并计算溶血评分（H-评分）。该研究获得了机构审查委员会（EK FaF UK 02/2018）的批准。与对照组相比，HFrEF 患者的血清 miR-21 水平降低（ < 0.05），与纽约心脏协会分级、左心室射血分数或 N-末端脑钠肽原水平无关。与血细胞比容正常的患者相比，贫血患者的 miR-21 水平明显降低（ < 0.05）。我们发现 miR-21 与血细胞比容（ < 0.05）和血红蛋白浓度（ < 0.05）之间存在显著关系。重要的是，我们在 HFrEF 患者队列中发现了血细胞比容与样本 H-评分之间的相关性（ < 0.05）；然而，溶血与 miR-21 之间没有相关性。HFrEF 患者的循环 miR-21 水平降低，血细胞比容被确定为与这种异常相关的因素。这表明 miR-21 反映了 HFrEF 患者的其他特征，而不是 HF 严重程度和进展的标准指标。
